We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 137

Northern exposure?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Door to software and business method patents clicks open in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 15 2010

The Federal Court of Canada has opened the door to software and business method patents in Canada by decisively overruling1 the decision of the Commissioner of Patents in Amazon.com Inc.’s application for its 1-Click online ordering system

Novo Nordisk v. Cobalt Pharmaceuticals, S. 55.2 proceeding, Repaglinide, Aug. 3, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 26 2010

Cobalt served a NOA with respect to repaglinide, the S enantiomer of a previously disclosed racemic compound (the “388 compound”), alleging invalidity of the '851 patent on grounds of anticipation, obviousness and s. 53(1

Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness

Sandoz Canada v Abbott Laboratories, appeal and cross-appeal of PMNOC decision, Clarithromycin extended-release, June 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 26 2010

Sandoz served a notice of allegation ("NOA") upon Abbott and filed an Abbreviated New Drug Submission ("ANDS") with respect to clarithromycin extended-release

Apotex Inc. v. Pfizer Ireland Pharmaceuticals (2010 FC 968)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

Apotex appealed an Order of Prothonotary Aalto dismissing a motion to strike parts of Pfizer’s Statement of Defence relating to res judicata, estoppel (issue and collateral), comity and abuse of process

Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998

Novopharm Limited v. Pfizer Canada inc. (2010 FCA 242)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

Novopharm appealed the decision of the Federal Court to grant an order of prohibition to Pfizer in respect of Novopharm’s generic version of VIAGRA

Eli Lilly Canada inc. v. Apotex Inc. (2010 FC 952)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

Apotex brought a motion to set aside an Order from 2007 granting Eli Lilly’s applications for a prohibition Order in PMNOC proceedings

Novopharm Limited v. Eli Lilly and Company (2010 FC 915)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy